Biopharmaceutical companies are transitioning from “quality-by-testing” philosophy to “quality-by-design” paradigms, and establishing QbD-based PAT tools to increase product and process understanding. Due to the deficit of analytical methods to support QbD-driven continuous bioprocessing, biopharmaceutical companies are actively developing PAT tools to comply with QbD regulations.
Europe Broadcast: Wednesday, Sept. 30, 2020 at 9am EDT | 2pm BST | 3pm CEST
US Broadcast: Wednesday, Sept. 30, 2020 at 2pm EDT | 1pm CDT | 11am PDT
On demand available after final airing until Sept. 30, 2021.